Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...
Investor's Business Daily on MSN4h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy PointsNetflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
Health-care company stocks fell as U.S. regulators look to crack down on prices and companies battle over market share of popular drugs. The Federal Trade Commission sued the drug middlemen that ...
The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and UnitedHealth Group Inc., alleging that they artificially pumped up prices of insulin ...
The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback